Package Leaflet: Information for the User
Ketorolaco Kabi 30 mg/ml Solution for Injection EFG
ketorolaco trometamol
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
|
Contents of the pack:
Ketorolaco Kabi contains a medicine called ketorolaco trometamol. This is a "non-steroidal anti-inflammatory" (NSAID) medicine.
Ketorolaco is used in hospitals to relieve pain after operations in patients 16 years of age and older. Ketorolaco can reduce pain, swelling, redness and heat (inflammation).
You must not be given ketorolaco if you are allergic (hypersensitive) to:
You must not be given ketorolaco if:
Do not receive ketorolaco if you are in any of the above situations. If you are not sure, tell your doctor or nurse before you are given ketorolaco.
Ketorolaco contains alcohol and is therefore not suitable for epidural or intrathecal use (injection into the spine).
Warnings and precautions
Severe skin reactions have been reported with the use of NSAIDs, appearing as red patches, generalised redness of the skin, ulcers or widespread rash accompanied by symptoms such as fever (see section 4). The rash may progress to widespread blistering or peeling of the skin. The highest risk of severe skin reactions is in the first weeks of treatment, but can occur at any time, including after long-term use (see section 4). If you have developed a severe skin reaction while taking Ketorolaco Kabi, you must not restart treatment at any time. If you develop a skin rash or these symptoms, stop treatment with Ketorolaco Kabi and contact your doctor or seek medical attention immediately.
Talk to your doctor or nurse before you are given ketorolaco. If you have heart problems, a previous stroke or think you might be at risk of these conditions (for example, if you have high blood pressure, diabetes or high cholesterol or if you smoke), you should discuss your treatment with your doctor or nurse.
Tell your doctor if you have recently had or are going to have stomach or gut surgery before you are given/take/use Ketorolaco Kabi, as Ketorolaco Kabi may sometimes worsen the healing of gut wounds after surgery.
Consult your doctor or nurse before you are given ketorolaco if:
If you suffer from any of the above conditions, or if you are not sure, talk to your doctor or nurse before you are given ketorolaco.
Use in children and adolescents
Ketorolaco is not recommended for use in children under 16 years of age.
Use with other medicines
Tell your doctor, pharmacist or nurse if you are taking, or have recently taken, any other medicines, including those obtained without a prescription.
In particular, tell your doctor or nurse if you are taking any of the following medicines before you are given ketorolaco:
If you are taking any of the above medicines, you must not be given ketorolaco.
Tell your doctor or nurse if you are taking:
If you are in any of the above situations, or if you are not sure, talk to your doctor or nurse before you are given ketorolaco.
Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Do not take ketorolaco if you are in the last 3 months of pregnancy, as it may harm your baby or cause problems during delivery. It may cause kidney and heart problems for your baby. It may affect you and your baby's ability to clot and prolong or delay delivery more than expected. You must not take ketorolaco during the first 6 months of pregnancy unless it is strictly necessary and your doctor has told you to. If you need treatment during this period or while trying to become pregnant, you will need to take the lowest dose for the shortest possible time. From the 20th week of pregnancy, ketorolaco may cause kidney problems for your baby if taken for more than a few days, which may cause low levels of the fluid surrounding the baby (oligohydramnios). If you need treatment for more than a few days, your doctor may recommend additional checks.
Ketorolaco may make it more difficult to become pregnant. Tell your doctor if you are planning to become pregnant or if you are having problems becoming pregnant.
You must not be given ketorolaco if you are pregnant, in labour or breast-feeding.
Driving and using machines
Ketorolaco may cause you to feel tired, sleepy, dizzy, have problems with your balance or vision, depression or difficulty sleeping. Talk to your doctor if you experience any of these and do not drive or use tools or machines.
Ketorolaco Kabi contains sodium and alcohol
This medicine contains less than 23 mg of sodium (1mmol) per 1 ml ampoule, which is essentially "sodium-free".
This medicine contains 100 mg of alcohol (ethanol) per vial, which is equivalent to 100 mg/ml (9.9% p/v). The amount contained in 1 ml of this medicine is equivalent to less than 2.5 ml of beer or 1 ml of wine.
The small amount of alcohol in this medicine will not have a noticeable effect.
Ketorolaco will be given to you by a doctor or nurse. It will be given by injection into a muscle (such as in your arm) or into a vein.
Medicines like ketorolaco may be associated with a small increased risk of heart attack ("myocardial infarction") or stroke. Any risk is more likely with higher doses and longer-term treatment.
The maximum treatment duration should be 2 days.
Use in children and adolescents
Ketorolaco is not recommended for use in children under 16 years of age.
Use in adults
Use in patients over 65 years of age, or with kidney problems or who weigh less than 50 kg
If you have any further questions on the use of this product, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Medicines like ketorolaco may be associated with a small increased risk of heart attack ("myocardial infarction") or stroke.
Serious side effects
Tell a doctor or nurse IMMEDIATELY if you get any of the following. You may need urgent medical treatment:
Severe stomach or gut problems, the signs include:
Allergic reactions, the signs include:
Severe skin rashes, the signs include:
Heart attack, the signs include:
Stroke, the signs include:
Meningitis, the signs include:
Liver problems, the signs include:
Urinary problems, the signs include:
If you notice any of the above serious side effects, tell a doctor or nurse immediately.
Other side effects
Tell your doctor or nurse if you get any of the following:
Stomach and gut
Blood
Mental health
Nervous system
Eyes and ears
Heart and circulation
Chest
Skin and hair
Urinary system
Other
If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or nurse.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Vigilance System for Human Use: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton or on the label of the ampoules after EXP. The expiry date refers to the last day of that month.
Store the ampoules in the outer packaging to protect them from light.
Short-term storage at low temperatures (down to -20°C) is allowed for up to 3 weeks.
Before administration, the product must be inspected visually. Do not use this medicine if you notice particles.
Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to a pharmacy for disposal. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Ketorolaco Kabi:
Appearance of the Product and Container Content
Ketorolaco Kabi is a clear, slightly yellow injectable solution. This injectable solution can be further diluted to attenuate it before administration.
Ketorolaco Kabi is supplied in glass ampoules containing 1 ml of solution, in packs of 5, 6, or 10.
Only some package sizes may be marketed.
Marketing Authorization Holder:
Fresenius Kabi España, S.A.U.
Marina 16-18
08005 Barcelona
Spain
Manufacturer:
S.C. Rompharm Company S.R.L.
Str. Eroilor, no. 1A
075100, Otopeni, Ilfov County,
Romania
Date of Last Revision of this Leaflet: January 2024
"Detailed information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es"
------------------------------------------------------------------------------------------------------------------------
The following information is intended only for healthcare professionals:
Posology and Method of Administration.
Ketorolac is administered by intravenous or intramuscular injection.
Adults
The recommended initial dose of ketorolac is 10 mg, followed by a dose of 10 to 30 mg every 4 to 6 hours, as needed. The total daily dose should not exceed 90 mg. The maximum duration of treatment should not exceed two days.
Elderly
The elderly have a higher risk of suffering from the serious consequences of adverse reactions. The total daily dose should not exceed 60 mg (see section 4.4).
Pediatric Population
Ketorolac is not recommended for use in children under 16 years of age.
Renal Impairment
Ketorolac is contraindicated in moderate to severe renal impairment; and a reduced dose should be administered in patients with mild renal impairment (not exceeding an IV or IM dose of 60 mg/day).
Incompatibilities
Ketorolac should not be mixed in a small volume (e.g., in a syringe) with morphine sulfate, meperidine hydrochloride, promethazine hydrochloride, or hydroxyzine hydrochloride, as precipitation of ketorolac may occur.
Ketorolac is compatible with 0.9% sodium chloride, 5% glucose, Ringer's 5%, and Ringer's lactate solutions. The compatibility of ketorolac with other medications is unknown.
Special Precautions for Storage
Keep the ampoules in the outer packaging to protect them from light.
Short-term periods of low temperatures (up to 3 weeks) up to -20°C are allowed.
Special Precautions for Disposal
There are no special instructions.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.